Ubiquitin-like Molecule ISG15 Acts as an Immune Adjuvant to Enhance Antigen-specific CD8 T-cell Tumor Immunity

Daniel O. Villarreal(University of Pennsylvania), David B. Weiner(The Wistar Institute), Rebekah J Siefert(University of Pennsylvania), Jian Yan(Inovio Pharmaceuticals (United States)), Megan C. Wise(Princess Alexandra Hospital), Laurence M. Wood(Texas Tech University)
Molecular Therapy
June 30, 2015
10.1038/mt.2015.120
Cited by 65

Related Papers

Immunogenicity of a DNA vaccine candidate for COVID-19
|Nature Communications|2020|641
Improved Survival in ARDS Patients Associated with a Reduction in Pulmonary Capillary Wedge Pressure
|CHEST Journal|1990|296
Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery
|The Journal of Infectious Diseases|2013|198
Elevated Expression of ISG15 in Tumor Cells Interferes with the Ubiquitin/26S Proteasome Pathway
|Cancer Research|2006|194
Coimmunization with an Optimized IL-15 Plasmid Results in Enhanced Function and Longevity of CD8 T Cells That Are Partially Independent of CD4 T Cell Help
|The Journal of Immunology|2005|184